Telix Pharmaceuticals Limited American Depositary Shares (TLX)
Stock · NASDAQ · Health Care
$10.71as of 10/16/2026
Price chart
Active signals
TLX Signal Track Record
How signals performed across all stocks →What TLX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 9 | +1.3% | 67% | September 21, 2026 |
| Bollinger Band Breakout | 6 | -1.1% | 50% | September 15, 2026 |
| Bollinger Band Breakdown | 4 | +1.4% | 50% | May 22, 2026 |
| Any 20-session window (baseline) | +0.4% | 50% |
Computed by MarketWall from daily closing prices since September 4, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clini…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,120
- Website
- telixpharma.com
Fundamentals
- 1-day range
- $10.66$10.94
- Market cap
- $3.60B
- P/E (trailing)
- —
- P/E (forward)
- -401.37
- EPS (trailing)
- $-0.02
- Dividend yield
- —
- Beta
- 0.60
- Avg. volume
- 276.7K
Forecasts
5 analyst ratings
Telix Pharmaceuticals Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment EducationYahoo · 10/9/2026
- Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigenbenzinga · 10/9/2026
- Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareYahoo · 10/9/2026
- Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane AntigenBenzinga · 10/9/2026
- Telix to Host Capital Markets Day in Melbourne on November 4, 2026Yahoo · 10/8/2026
- Telix Pharmaceuticals: Merger Bodes Well For Long-Term PlanSeekingAlpha · 10/8/2026
- First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)Yahoo · 10/6/2026
- Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma ImagingBenzinga · 10/6/2026
- Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to TradeYahoo · 9/30/2026
Insider Activity
Insider Actions →- Smith Darren Charlton · September 7, 2026 · Buy2.1K @ $9.66
- Behrenbruch Christian · April 29, 2026 · Buy33.4K @ $14.87
- Behrenbruch Christian · April 28, 2026 · Buy34.5K @ $14.48
Institutional Ownership
March 31, 2026
- Total shares held
- 2.51M
- Total value held
- $23.95M
- Institutional holders
- 37
- Unknown564.8K
- Unknown541.3K
- Unknown289.9K
- Unknown266.2K
- Unknown174.4K
- Unknown164.4K
- Unknown130.0K
- Unknown116.4K
- Unknown43.4K
- Unknown34.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Telix doses first US patients with FDA-approved Pixclara
Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.
Telix doses first US patients with FDA-approved Pixclara. Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.